ArticleHematology reports2021
Heparin-induced thrombocytopenia and COVID-19.
Article in Hematology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Significance of heparin induced thrombocytopenia (HIT) in COVID-19: a systematic review and meta-analysis.Journal of thrombosis and thrombolysis · 2023Pooled it
- A Functional Assay for the Determination of Heparin-Induced Thrombocytopenia via Flow Cytometry.Diagnostics (Basel, Switzerland) · 2023Article
- Glycosylation in SARS-CoV-2 variants: A path to infection and recovery.Biochemical pharmacology · 2022Review
- Prognosing the risk of COVID-19 death through a machine learning-based routine blood panel: A retrospective study in Brazil.International journal of medical informatics · 2022Article
- Accelerated heparin-induced thrombocytopenia in a COVID-19 patient; a case report with literature review.Annals of medicine and surgery (2012) · 2022Article
- Mechanisms of Immunothrombosis by SARS-CoV-2.Biomolecules · 2021Review
- The complicated relationships of heparin-induced thrombocytopenia and platelet factor 4 antibodies with COVID-19.International journal of laboratory hematology · 2021Review
- Autoimmune heparin-induced thrombocytopenia: a rare manifestation of COVID-19.BMJ case reports · 2021Article
- Is the heparin-induced thrombocytopenia-like syndrome associated with ChAdOx vaccine related to the vaccine itself or to an autoimmune reaction to severe acute respiratory syndrome 2 coronavirus: insights and implications from previous reports in infected cases?New microbes and new infections · 2021Article
- Thrombotic thrombocytopenia associated with COVID-19 infection or vaccination: Possible paths to platelet factor 4 autoimmunity.PLoS medicine · 2021Review
- Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19.SN comprehensive clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heparin-induced thrombocytopenia (HIT) has not been included as a possible cause of thrombocytopenia in Coronavirus Disease 2019 (COVID-19) patients. We report a case of HIT in a patient with COVID-19 treated with heparin. A 78-yearold man was admitted to our hospital for acute respiratory failure and acute renal failure due to SARS-CoV-2 infection; in intensive care unit, one 5000IU heparin dose (day 0, platelet count 305000/μL). On day 2, haemoglobin started to decrease and heparin was stopped. On day 10, platelet count was 153000/μL and 5000IU calcium heparin subcutaneously twice daily was started. The platelet further decreased, reaching 49000/μL on day 17, and the patient was investigated for suspected HIT: an IgG specific chemiluminescence test for heparin- PF4 antibodies was positive and a femoral DVT was found at ultrasound. Argatroban was started, platelet count increased without any bleeding and thrombosis complication. Our experience shows that HIT may develop in heparin treated COVID-19 patients and should be included among the possible cause of thrombocytopenia in such patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.